GALE-301

DB17262InvestigationalProtein Based Therapies

GALE-301 is an investigational cancer immunotherapy. It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor...

Mechanism: Pharmacologically active on HLA class I histocompatibility antigen, A alpha chain
Curator reviewed
Code names: GALE-301

Resolves to

Targets

P04439HLA-A

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with GALE-301, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account